Royal London Asset Management Ltd. Takes Position in Becton Dickinson and Co (BDX)

Royal London Asset Management Ltd. acquired a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 114,116 shares of the medical instruments supplier’s stock, valued at approximately $25,333,000.

Several other institutional investors have also bought and sold shares of BDX. Morgan Stanley increased its holdings in shares of Becton Dickinson and by 133.0% in the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock worth $723,303,000 after purchasing an additional 1,581,829 shares in the last quarter. FMR LLC boosted its stake in shares of Becton Dickinson and by 8.0% in the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after buying an additional 1,286,579 shares during the last quarter. Cornerstone Wealth Management LLC boosted its stake in shares of Becton Dickinson and by 233.6% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock worth $3,286,000 after buying an additional 453,623 shares during the last quarter. Vanguard Group Inc boosted its stake in shares of Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after buying an additional 283,433 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Becton Dickinson and by 1.3% during the third quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after purchasing an additional 283,433 shares in the last quarter. 86.28% of the stock is owned by institutional investors and hedge funds.

In related news, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $252.37, for a total value of $1,485,702.19. Following the transaction, the executive vice president now owns 6,013 shares in the company, valued at $1,517,500.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the sale, the senior vice president now directly owns 4,497 shares in the company, valued at $1,105,497.51. The disclosure for this sale can be found here. Insiders have sold a total of 13,210 shares of company stock worth $3,275,587 in the last quarter. Company insiders own 0.12% of the company’s stock.

Several research analysts recently issued reports on the stock. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. Piper Jaffray Companies boosted their price objective on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a report on Tuesday, February 5th. Morgan Stanley dropped their price objective on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Finally, Citigroup lowered their price target on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $253.17.

NYSE BDX opened at $245.05 on Thursday. The company has a market capitalization of $65.45 billion, a PE ratio of 22.26, a P/E/G ratio of 1.70 and a beta of 1.23. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the business earned $2.48 EPS. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, sell-side analysts forecast that Becton Dickinson and Co will post 12.1 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s payout ratio is 27.97%.

COPYRIGHT VIOLATION NOTICE: “Royal London Asset Management Ltd. Takes Position in Becton Dickinson and Co (BDX)” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/02/14/114116-shares-in-becton-dickinson-and-co-bdx-acquired-by-royal-london-asset-management-ltd.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: What is the NASDAQ Stock Market?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply